BTIG Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $5
BTIG analyst Kaveri Pohlman initiates coverage on Oncternal Therapeutics (NASDAQ:ONCT) with a Buy rating and announces Price Target of $5.
Vaccinex And 4 Other Penny Stocks Bought By Insiders
The unemployment rate in the Eurozone dropped to a record low of 7% in December from a revised 7.1% level in the previous month, helping the STOXX Europe 600 Index record gains this morning. Investors, meanwhile, focused on some notable insider trades.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Oncternal Therapeutics (NASDAQ:ONCT) shares moved upwards by 7.0% to $2.0 during Monday's after-market session. The company's market cap stands at $98.8 million.
Oncternal, FDA In Pact For Pivotal Study Design For Zilovertam In Mantle Cell Lymphoma
The FDA and Oncternal Therapeutics Inc (NASDAQ: ONCT) have
Oncternal Therapeutics Announces Consensus With FDA On Phase 3 Registrational Study Design For Zilovertamab In Treatment Of Mantle Cell Lymphoma
The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib
The FDA also
Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At ASH 2021; Reports Objective Response Rate Of 81%; Complete Response Rate Of 35%
Updated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) data from the CIRLL study are encouraging, and comparable to previous results presented at ASCO 2021
Objective response rate (ORR)
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Oncternal Therapeutics Reports Pre-Clinical Data From ONCT-534 Accepted For Poster Presentation At AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Oct. 7, 2021 At 9 a.m. EDT
Androgen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice variants (AR-SV),